About Us

ThioLogics is a new biotechnology company that has developed a groundbreaking site-specific conjugation platform that will enable the assembly of the next generation of antibody-drug conjugates. Based on propriety chemistries arising from the laboratories of its University College London founders, Professor Stephen Caddick, Dr James Baker and Dr Vijay Chudasama, Thiologics has developed a conjugation platform that allows the selective, stable and functional modification of disulfide bonds or free cysteine in peptides, proteins and antibodies.